Toxicities of chimeric antigen receptor T cells: recognition and management.

By Jennifer N. Brudno, J. Kochenderfer. Blood, 2016

1,293 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/5b3a100941a06840ca954978575c4e77570e5ad2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomedical Engineering

1. J. Kochenderfer
2. Jennifer N. Brudno
3. Rahul Satija

In Genetics

1. J. Kochenderfer
2. Jennifer N. Brudno
3. Ewan Birney
4. John C. Marioni
5. Martin Hemberg
6. A. Shalek
7. Rahul Satija
8. Eric S. Lander

In Oncology

1. J. Kochenderfer
2. Jennifer N. Brudno
3. Ehud Y. Shapiro
4. Padmanee Sharma
5. Eric S. Lander

Citations in the corpus

• FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome (2018, background): “Fever and tachycardia reportedly resolved within hours after infusion of tocilizumab [2, 5, 11, 14], but resolution of hypotension and organ Table 1.”
• New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management (2017, background): “every 6 h until neurotoxicity has improved to at least grade 1, or until at least eight doses have been administered [9].”
• The Human Cell Atlas (2017, background): “…studying development or comparing a model system to human biology, medical scientists examining the effect of a disease-causing mutation, and drug developers concerned about the potential toxicities of a small molecule or a CAR-T cell targeting a specific protein (Brudno and Kochenderfer, 2016).”
• Cytokine release syndrome (2018, background): “Subsequent studies confirmed that administration of monoclonal antibodies against IL-6 (siltuximab) and its receptor (tocilizumab) led to rapid resolution of CRS symptoms [29, 31, 33, 71].”
• Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells (2017, neutral): “084 CLL 16 (67) 2 (8) 6 (25) 24 NHL 42 (68) 12 (19) 8 (13) 62 Race, n (%) White 62 (56) 22 (20) 26 ( 24 ) 110 0.”
• Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses (2018, neutral): “Due to the fixed design that limited the controllability of CAR T cell activation level, managing CAR T cell-related toxicities have proven to be challenging (Brentjens et al., 2013; Brudno and Kochenderfer, 2016; Davila et al., 2014).”